Knowledge Library
AACR 2023: Integrated platform enables KRAS-targeted drugs discovery
Discover our end-to-end KRAS services platform presented at AACR 2023! WuXi AppTec scientists have established a comprehensive panel of assays on key mutants of KRAS, including G12C and G12D, to empower KRAS-targeted drug discovery. Our suite of services includes 2D/3D cell proliferation assays (utilizing cell lines harboring single or double KRAS mutations) as well as …Read More >
Ready-to-Go Biophysical Assays
We offer a comprehensive platform of biophysical screening assays to measure protein binding, thermodynamics, stoichiometry, protein quality, and kinetics to accelerate your drug discovery programs.
Cutting-Edge Crystallography Services
Discover our comprehensive structure generation platform for challenging targets, with our high resolution and high throughput crystallization services to support hit finding through to lead optimization.
Crystal-Grade Protein Production
With a focus on quality and stability, gain access to our established systems, strategies, and advanced co-expression vectors to address even the most significant challenges of recombinant protein production.
Discovery Newsletter: April 2023
In this month’s newsletter, learn more about our comprehensive panel of CDK4/6 inhibitor-resistant breast cancer models and in vitro imaging assays for compound profiling. We also showcase our recent publications describing the development of HBV antigen inhibitors and noncovalent inhibitors of the SARS-CoV-2 3C-like protease (3CLpro).
Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro
The 3C-like protease (3CLpro) is an essential enzyme for the replication of SARS-CoV-2 and thus is a target for drug discovery teams. Nearly all inhibitors of coronavirus 3CLpro reported so far are covalent inhibitors. Here, we report the development of specific, noncovalent inhibitors of 3CLpro with high in vivo efficacy in mice. One compound, WU-04, …Read More >
Targeted Protein Degradation
WuXi AppTec utilizes state-of-the-art techniques to support drug discovery teams focused on targeted protein degradation. Our services include a broad range of ligand-finding methods, such as DEL, fragment screening, ASMS, and virtual screening. We provide custom linker design and complex synthesis for new linkers and E3 ligase ligands. To support lead optimization efforts, our platform …Read More >
Ligand Finding and Chemistry Workflows for Targeted Protein Degradation
This webinar will focus on aspects related to PROTAC discovery and chemistry workflows, such as ligand finding strategies, synthesis optimization, and linker design. Successful development of bifunctional molecules requires a deep understanding of multiple processes, including biophysical events which dictate induced proximity and how technologies such as DNA-encoded libraries (DEL) can be leveraged to identify …Read More >
Drugging the Undruggable: Leveraging the Right Screening Methods for Challenging Targets
Challenging targets, such as membrane proteins or protein-protein interactions were considered undruggable in the past. However, today a variety of screening methods can be used to help develop drugs against these formerly undruggable targets.